2024-01-24 09:36:36 ET
More on Cytokinetics
- Cytokinetics Steps Up As Prime Target After Aficamten's HCM Triumph (Rating Upgrade)
- Cytokinetics: Clear Win For Aficamten In SEQUOIA-HCM Phase 3 Trial (Upgrade)
- Cytokinetics: Buyout Rumors Ahead Of The Key Phase 3 Readout Of Aficamten
- Amgen may be evaluating Cytokinetics bid; CYTK wants $130-$145 a share - report (update)
- Cytokinetics plunges amid no deal announcement, Novartis backing away (update)
Read the full article on Seeking Alpha
For further details see:
UBS cuts Cytokinetics to neutral, sees takeout valuation at $105